Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.99
-0.20 (-3.23%)
Mar 12, 2026, 1:55 PM EDT - Market open
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$303,078
Profits / Employee
-$2,053,637
Market Cap
526.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 24 | 30.77% |
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Lyell Immunopharma | 300 |
| Rocket Pharmaceuticals | 202 |
| CorMedix | 191 |
| Prothena Corporation | 163 |
| Invivyd | 100 |
| Neumora Therapeutics | 95 |
| Fulcrum Therapeutics | 55 |
VSTM News
- 7 days ago - Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 22 days ago - Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
- 5 weeks ago - Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 2 months ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC - Seeking Alpha
- 2 months ago - Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
- 3 months ago - Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth - Business Wire